Teplizumab for Japanese with early-stage type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are Japanese (born in Japan or have 4 Japanese-born grandparents).
- You are between 1 and 34 years old.
- You have been diagnosed with stage 2 type 1 diabetes, meaning 2 or more diabetes-related antibodies are present and your blood sugar is higher than normal without being full diabetes.
- You are generally healthy except for this early diabetes.
- You are up to date on routine vaccinations.
- If you are a woman who could become pregnant, you must use highly effective birth control or not have sex during the study and for a time after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This early-stage trial is testing a new approach to slow or stop the loss of insulin-making cells in people who were recently diagnosed with type 1 diabetes. It uses a medicine called teplizumab to adjust the immune system, and the goal is to help you keep making your own insulin for as long as possible.
This study compares two medicines (teplizumab and anti-thymocyte globulin) to see if they can delay the onset of type 1 diabetes in people who are at high risk but don't have symptoms yet. If you have certain diabetes-related antibodies in your blood, this trial might help keep full-blown diabetes away for longer.
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
This study watches people with stage 2 type 1 diabetes who either get teplizumab or not, to compare their real-world experiences. It helps researchers learn how the drug affects daily life.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.